X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs STERLING BIOTECH - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA STERLING BIOTECH SANOFI INDIA/
STERLING BIOTECH
 
P/E (TTM) x 39.9 -0.4 - View Chart
P/BV x 8.6 0.0 61,209.7% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 SANOFI INDIA   STERLING BIOTECH
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
STERLING BIOTECH
Dec-13
SANOFI INDIA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs4,56011 43,428.6%   
Low Rs4,4003 129,411.8%   
Sales per share (Unadj.) Rs1,028.526.8 3,836.7%  
Earnings per share (Unadj.) Rs129.0-15.0 -862.2%  
Cash flow per share (Unadj.) Rs186.0-5.5 -3,404.4%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.654.9 1,373.2%  
Shares outstanding (eoy) m23.03267.87 8.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.40.3 1,680.1%   
Avg P/E ratio x34.7-0.5 -7,476.0%  
P/CF ratio (eoy) x24.1-1.3 -1,893.4%  
Price / Book Value ratio x5.90.1 4,694.3%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1741,862 5,542.0%   
No. of employees `0003.61.4 267.6%   
Total wages/salary Rs m3,592547 656.9%   
Avg. sales/employee Rs Th6,537.75,303.3 123.3%   
Avg. wages/employee Rs Th991.4403.8 245.5%   
Avg. net profit/employee Rs Th819.8-2,959.0 -27.7%   
INCOME DATA
Net Sales Rs m23,6867,181 329.9%  
Other income Rs m70843 1,662.0%   
Total revenues Rs m24,3947,223 337.7%   
Gross profit Rs m5,281947 557.7%  
Depreciation Rs m1,3132,543 51.6%   
Interest Rs m154,377 0.3%   
Profit before tax Rs m4,661-5,931 -78.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691-1,924 -87.9%   
Profit after tax Rs m2,970-4,007 -74.1%  
Gross profit margin %22.313.2 169.1%  
Effective tax rate %36.332.4 111.8%   
Net profit margin %12.5-55.8 -22.5%  
BALANCE SHEET DATA
Current assets Rs m15,67314,335 109.3%   
Current liabilities Rs m6,67849,809 13.4%   
Net working cap to sales %38.0-494.0 -7.7%  
Current ratio x2.30.3 815.5%  
Inventory Days Days76403 18.8%  
Debtors Days Days22171 13.1%  
Net fixed assets Rs m8,09855,432 14.6%   
Share capital Rs m230268 86.0%   
"Free" reserves Rs m17,08813,935 122.6%   
Net worth Rs m17,35614,701 118.1%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m25,40073,988 34.3%  
Interest coverage x311.7-0.4 -87,821.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.1 960.8%   
Return on assets %11.80.5 2,346.2%  
Return on equity %17.1-27.3 -62.8%  
Return on capital %26.9-6.4 -419.3%  
Exports to sales %24.525.9 94.6%   
Imports to sales %28.00.2 16,467.7%   
Exports (fob) Rs m5,8011,860 311.9%   
Imports (cif) Rs m6,62712 54,319.7%   
Fx inflow Rs m7,1451,860 384.2%   
Fx outflow Rs m6,84625 27,505.0%   
Net fx Rs m2991,835 16.3%   
CASH FLOW
From Operations Rs m3,2261,719 187.7%  
From Investments Rs m-1,555-3,148 49.4%  
From Financial Activity Rs m-1,8181,426 -127.5%  
Net Cashflow Rs m-147-3 4,323.5%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.0 -  
FIIs % 14.6 9.9 147.5%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.5 39.3 26.7%  
Shareholders   15,184 21,482 70.7%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY18); Net Profit Up 37.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, SANOFI INDIA has posted a net profit of Rs 825 m (up 37.5% YoY). Sales on the other hand came in at Rs 6 bn (up 11.7% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS